The role of mesangial homeostasis in glomerular injury progression: Hope for mesangial sclerosis reversal

Kidney International

Volumn 75, Issue 6, 2009, Pages 574-576

  Picken, Maria M ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN LIGHT CHAIN; INTERSTITIAL COLLAGENASE; MATRILYSIN; PARAPROTEIN; STROMELYSIN; TENASCIN;

CELL CULTURE; CLINICAL FEATURE; DIABETIC NEPHROPATHY; DISEASE COURSE; EXTRACELLULAR MATRIX; GLOMERULOSCLEROSIS; HOMEOSTASIS; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY INJURY; LIGHT CHAIN DEPOSITION DISEASE; MESANGIUM CELL; NOTE; PATHOGENESIS; PRIORITY JOURNAL;

EID: 61349180760     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.651     Document Type: Note

References (12)

1. Ronco P, Plaisier E, Mougenot B et al. Immunoglobulin light (heavy)-chain deposition disease: from molecular medicine to pathophysiology-driven therapy. Clin J Am Soc Nephrol 2006; 1: 1342-1350.
2. Picken MM. Immunoglobulin light and heavy chain amyloidosis AL/AH: renal pathology and differential diagnosis. Contrib Nephrol 2007; 153: 135-155.
3. Kapur U, Barton K, Fresco R et al. Expanding the pathologic spectrum of immunoglobulin light chain proximal tubulopathy. Arch Pathol Lab Med 2007; 131: 1368-1372.
4. Gu X, Herrera GA. Light-chain-mediated acute tubular interstitial nephritis: a poorly recognized pattern of renal disease in patients with plasma cell dyscrasia. Arch Pathol Lab Med 2006; 130: 265-269.
5. Godken N, Barlogie B, Liapis H. Morphologic heterogeneity of renal light-chain deposition disease. Ultrastruct Pathol 2008; 32: 17-24.
6. Salant DJ, Sanchorawala V, D'Agati VD. A case of atypical light chain deposition disease: diagnosis and treatment. Clin J Am Soc Nephrol 2007; 2: 858-867.
7. Kaplan B, Livneh A, Gallo G. Charge differences between in vivo deposits in immunoglobulin light chain amyloidosis and non-amyloid light chain deposition disease. Br J Haematol 2007; 136: 723-728.
8. Weichman K, Dember LM, Prokaeva T et al. Clinical and molecular characteristics of patients with non-amyloid light chain deposition disorders, and outcome following treatment with high-dose melphalan and autologous stem cell transplantation. Bone Marrow Transplant 2006; 38: 339-343.
9. Lorenz EC, Gertz MA, Fervenza FC et al. Long-term outcome of autologous stem cell transplantation in light chain deposition disease. Nephrol Dial Transplant 2008; 23: 2052-2057.
10. Hassoun H, Flombaum C, D'Agati VD et al. High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease. Bone Marrow Transplant 2008; 42: 405-412.
11. Keeling J, Herrera GA. An in vitro model of light chain deposition disease. Kidney Int 2009; 75; 634-645.
12. Ma LJ, Fogo AB. Modulation of glomerulosclerosis. Semin Immunopathol 2007; 29: 385-395.